Developer docs
API playgroundTry for free, no card

Search company profiles

Desyncra Technologies

Full company profile

uuid002wq8t

Namestring
Desyncra Technologies
Legal namestring
Desyncra Technologies Limited
Websiteurl
desyncra.com
Company typeenum
Private
Founded yearint
2015
Descriptiontext

Desyncra Technologies Limited is a UK-incorporated private medical technology company founded in 2015 that has developed CR® Neuromodulation, a proprietary acoustic therapy targeting chronic tinnitus. The technology works by delivering patient-specific therapeutic tones via a customized iPod device with custom-designed earphones, using a proprietary pitch-matching procedure to disrupt hyperactivity in tinnitus neuronal networks. Treatment spans a 36-week protocol with periodic optimization at 3, 8, 12, 24, and 36 weeks, and clinical evidence indicates that symptom reductions persist beyond the active therapy period as neuronal networks adapt. The platform has documented applicability potential to Parkinson's disease, epilepsy, and migraine, though tinnitus is the only commercialized indication today.

Desyncra for Tinnitus has secured FDA clearance in the United States and CE Mark certification in Europe, and is offered exclusively through a network of over 70 authorized audiology and ENT clinics in the US and Europe (Germany, UK, Switzerland, Austria, Belgium, Netherlands, Poland, Spain, France). The company does not sell directly to patients; instead, it provides the technology and customized devices to certified healthcare providers. International operations outside the UK are handled through a wholly-owned German subsidiary, Desyncra Operating GmbH. Distribution is supported by a Clinic Finder digital tool and a multi-language website (English, German, French, Spanish).

The business model combines technology licensing and hardware provision (customized iPod devices with proprietary earphones) sold or licensed to clinical providers. Revenue is generated per treatment course rather than through subscription or recurring SaaS contracts. The evidence base comprises five clinical studies covering 486+ patients across the UK, Germany, and Hungary, with publications in peer-reviewed journals including Frontiers in Neurology, BioMed Research International, Restorative Neurology and Neuroscience, and Ideggyogyaszati Szemle. Academic research partnerships include Stanford University, Veterans Affairs Portland, and centers in England and Germany.

Short descriptiontext

Desyncra Technologies is a UK-based medical technology company that has developed CR® Neuromodulation, an FDA-cleared, CE-marked acoustic therapy for chronic tinnitus delivered through a network of over 70 authorized audiology and ENT clinics across the US and Europe via a customized iPod device.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersLondon, United Kingdom
HQ citystring
London
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
neuromodulation therapy, tinnitus treatment, acoustic stimulation, medical device technology, neurological therapy
Industry1 code
PRIMARYHLACANAC
Non-prescription / OTC Digital Therapeutics
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
NAICS code1 code
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
SIC code2 codes
  • Surgical & Medical Instruments & Apparatus3841
  • Electromedical & Electrotherapeutic Apparatus3845
Product category
Neuromodulation Medical Devices
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Medical Device Technology Licensing
TypeHardware Sales
Description

Desyncra develops and provides CR® Neuromodulation technology to healthcare providers (audiologists, ENT clinics). The company is described as a technology developer and provider, with products distributed through authorized clinics rather than directly to patients.

desyncra.com
2Clinic Network Distribution
TypeLicensing Royalties
Description

Distribution of therapy systems through a network of over 70 authorized clinics across the United States and internationally (Germany, UK, Switzerland, Austria, Belgium, Netherlands, Poland, Spain, France).

desyncra.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Desyncra develops and supplies Desyncra™ for Tinnitus, a neuroscientific CR® Neuromodulation therapy that uses acoustic stimulation to disrupt hyperactivity in tinnitus neuronal networks. The therapy is delivered through customized iPod devices with custom-designed earphones over a 36-week treatment course, with therapeutic tones personalized to each patient via a proprietary pitch-matching procedure. The product carries FDA clearance and CE Mark and is distributed exclusively through authorized audiology and ENT clinics rather than sold directly to patients.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Over 3,000 tinnitus patients treated successfully
+2 more records
Product overview1 text field

Desyncra Technologies offers a single core product: Desyncra™ for Tinnitus, a neuroscientific therapy that applies CR® Neuromodulation to disrupt and desynchronize hyperactivity in tinnitus neuronal networks. The therapy is delivered via a customized iPod device with custom-designed earphones, with therapeutic tones tailored to each patient's exact tinnitus profile. The treatment spans 36 weeks with periodic optimization visits at 3, 8, 12, 24, and 36 weeks. The technology platform also shows potential for other neurological conditions including Parkinson's disease, epilepsy, and migraine.

Product and service1 record
1Desyncra™ for Tinnitus
CategoryNeuromodulation Medical Devices
Description

A 36-week acoustic neuromodulation therapy system that delivers CR® Neuromodulation via customized iPod devices and proprietary earphones, with therapeutic tones personalized to each tinnitus patient's exact pitch profile through a proprietary pitch-matching procedure. Provided to clinics for use with chronic tinnitus patients experiencing distressing loudness and annoyance.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Academic research partnership for CR® Neuromodulation clinical research, contributing to the company's evidence base and scientific validation.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Clinical research partnership contributing to the company's portfolio of peer-reviewed clinical studies on tinnitus treatment.

3Research Centers in England and Germany
Strategic tierCoreTypeStrategic or Co-development Partner
Description

International clinical research partnerships supporting multi-site clinical studies and European regulatory approvals (CE Mark).

desyncra.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
1MicroTransponder
TypeEmerging player
Description

US-based developer of paired vagus-nerve-stimulation therapy (Vivistim and SerenePath) targeting tinnitus and stroke-related indications; an early-stage neuromodulation peer with overlapping clinical-mechanism ambitions for tinnitus.

TypeBroad incumbent
Description

Global implantable hearing-solutions company (cochlear implants, bone-conduction systems); adjacent incumbent in the same neuro-otology and ENT prescribing channel as Desyncra's therapy.

TypeBroad incumbent
Description

Hearing-aid manufacturer (parent of ReSound and Beltone) with a ReSound Relief tinnitus app and integrated tinnitus therapy features, serving the same audiologist distribution channel that Desyncra targets.

4Oto (formerly Oto Health)
TypeEmerging player
Description

Digital/app-delivered tinnitus therapy (CBT-based) targeting the same patient population via direct-to-consumer and audiologist channels; competes for the underserved chronic-tinnitus segment Desyncra addresses.

TypeBroad incumbent
Description

Swiss parent of Phonak and other hearing-aid brands offering tinnitus therapy features inside hearing aids; a broad incumbent whose products sit alongside CR® in audiologists' tinnitus recommendation set.

TypeBroad incumbent
Description

Major hearing-aid manufacturer offering the Widex Zen tinnitus therapy/sound therapy program integrated into its hearing aids; competes for the same audiologist-channel tinnitus patient and shares Desyncra's positioning as an evidence-led therapy.

TypeDirect peer
Description

Ireland-based developer of Lenire, a bimodal (auditory + tongue) neuromodulation device FDA-cleared for tinnitus — the closest head-to-head competitor to Desyncra's CR® Neuromodulation, with a comparable clinic-distribution model.

TypeEmerging player
Description

US audiology clinic network specializing in tinnitus treatment; comparable as both an authorized Desyncra provider and a competitor channel offering alternative tinnitus therapies (CBT-based and sound-based) to similar patient cohorts.

TypeBroad incumbent
Description

Global hearing-aid brand with a dedicated tinnitus therapy feature set (Notch Therapy, built-in tinnitus notch) bundled with its core hearing-aid portfolio, offering ENT/audiology clinics an incumbent alternative to a standalone neuromodulation therapy.

TypeBroad incumbent
Description

Hearing-aid incumbent with a Tinnitus SoundSupport offering and clinical-evidence-heavy go-to-market through audiologists; competes for the same audiology-channel prescribing decision as Desyncra's CR® therapy.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability2 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Desyncra Technologies

Neuromodulation Medical Devicesdesyncra.com

Desyncra Technologies is a UK-based medical technology company that has developed CR® Neuromodulation, an FDA-cleared, CE-marked acoustic therapy for chronic tinnitus delivered through a network of over 70 authorized audiology and ENT clinics across the US and Europe via a customized iPod device.

What Desyncra Technologies does

Desyncra Technologies Limited is a UK-incorporated private medical technology company founded in 2015 that has developed CR® Neuromodulation, a proprietary acoustic therapy targeting chronic tinnitus. The technology works by delivering patient-specific therapeutic tones via a customized iPod device with custom-designed earphones, using a proprietary pitch-matching procedure to disrupt hyperactivity in tinnitus neuronal networks. Treatment spans a 36-week protocol with periodic optimization at 3, 8, 12, 24, and 36 weeks, and clinical evidence indicates that symptom reductions persist beyond the active therapy period as neuronal networks adapt. The platform has documented applicability potential to Parkinson's disease, epilepsy, and migraine, though tinnitus is the only commercialized indication today.

Desyncra for Tinnitus has secured FDA clearance in the United States and CE Mark certification in Europe, and is offered exclusively through a network of over 70 authorized audiology and ENT clinics in the US and Europe (Germany, UK, Switzerland, Austria, Belgium, Netherlands, Poland, Spain, France). The company does not sell directly to patients; instead, it provides the technology and customized devices to certified healthcare providers. International operations outside the UK are handled through a wholly-owned German subsidiary, Desyncra Operating GmbH. Distribution is supported by a Clinic Finder digital tool and a multi-language website (English, German, French, Spanish).

The business model combines technology licensing and hardware provision (customized iPod devices with proprietary earphones) sold or licensed to clinical providers. Revenue is generated per treatment course rather than through subscription or recurring SaaS contracts. The evidence base comprises five clinical studies covering 486+ patients across the UK, Germany, and Hungary, with publications in peer-reviewed journals including Frontiers in Neurology, BioMed Research International, Restorative Neurology and Neuroscience, and Ideggyogyaszati Szemle. Academic research partnerships include Stanford University, Veterans Affairs Portland, and centers in England and Germany.

Desyncra Technologies firmographics

Firmographics
Name
Desyncra Technologies
Legal name
Desyncra Technologies Limited
Website
https://desyncra.com
Company type
Private
Founded year
2015
Operating status
Operating
Headcount range
1–10 employees
Short description
Desyncra Technologies is a UK-based medical technology company that has developed CR® Neuromodulation, an FDA-cleared, CE-marked acoustic therapy for chronic tinnitus delivered through a network of over 70 authorized audiology and ENT clinics across the US and Europe via a customized iPod device.
Ownership category
akta.pro rank

Desyncra Technologies industry classification

Industry
Product category
Neuromodulation Medical Devices
NAICS
Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
SIC
Surgical & Medical Instruments & Apparatus (3841), Electromedical & Electrotherapeutic Apparatus (3845)
akta.pro industry
PRIMARYHLACANAC
Non-prescription / OTC Digital Therapeutics
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)

Keywords

  • Neuromodulation therapy
  • Tinnitus treatment
  • Acoustic stimulation
  • Medical device technology
  • Neurological therapy

Where Desyncra Technologies is headquartered

Location

Headquarters

HQ city
London
HQ country
United Kingdom
HQ region
Europe

Offices2 records

Markets served

Desyncra Technologies business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales

Revenue model

  1. Medical Device Technology Licensing: Desyncra develops and provides CR® Neuromodulation technology to healthcare providers (audiologists, ENT clinics). The company is described as a technology developer and provider, with products distributed through authorized clinics rather than directly to patients.
  2. Clinic Network Distribution: Distribution of therapy systems through a network of over 70 authorized clinics across the United States and internationally (Germany, UK, Switzerland, Austria, Belgium, Netherlands, Poland, Spain, France).

Go-to-market motion1 record

Distribution channels3 records

Marketing channels4 records

Desyncra Technologies product offering

Product offering

Core offering

Desyncra develops and supplies Desyncra™ for Tinnitus, a neuroscientific CR® Neuromodulation therapy that uses acoustic stimulation to disrupt hyperactivity in tinnitus neuronal networks. The therapy is delivered through customized iPod devices with custom-designed earphones over a 36-week treatment course, with therapeutic tones personalized to each patient via a proprietary pitch-matching procedure. The product carries FDA clearance and CE Mark and is distributed exclusively through authorized audiology and ENT clinics rather than sold directly to patients.

Product overview

Desyncra Technologies offers a single core product: Desyncra™ for Tinnitus, a neuroscientific therapy that applies CR® Neuromodulation to disrupt and desynchronize hyperactivity in tinnitus neuronal networks. The therapy is delivered via a customized iPod device with custom-designed earphones, with therapeutic tones tailored to each patient's exact tinnitus profile. The treatment spans 36 weeks with periodic optimization visits at 3, 8, 12, 24, and 36 weeks. The technology platform also shows potential for other neurological conditions including Parkinson's disease, epilepsy, and migraine.

Differentiator

Problem solved

Functional benefit

Products and services

  • Desyncra™ for Tinnitus A 36-week acoustic neuromodulation therapy system that delivers CR® Neuromodulation via customized iPod devices and proprietary earphones, with therapeutic tones personalized to each tinnitus patient's exact pitch profile through a proprietary pitch-matching procedure. Provided to clinics for use with chronic tinnitus patients experiencing distressing loudness and annoyance.

Quantifiable outcome

  • Over 3,000 tinnitus patients treated successfully
  • +2 more outcomes

Companies that use Desyncra Technologies

Customer profile

Segments2 records

Ideal customer profiles1 record

Desyncra Technologies technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature3 records

Desyncra Technologies partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core.

  • Stanford UniversitycoreStrategic or Co-development PartnerAcademic research partnership for CR® Neuromodulation clinical research, contributing to the company's evidence base and scientific validation.
  • Veterans Affairs PortlandcoreStrategic or Co-development PartnerClinical research partnership contributing to the company's portfolio of peer-reviewed clinical studies on tinnitus treatment.
  • Research Centers in England and GermanycoreStrategic or Co-development PartnerInternational clinical research partnerships supporting multi-site clinical studies and European regulatory approvals (CE Mark).

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Desyncra Technologies competitors and assessment

Company assessment

Emerging players

  • MicroTransponder: US-based developer of paired vagus-nerve-stimulation therapy (Vivistim and SerenePath) targeting tinnitus and stroke-related indications; an early-stage neuromodulation peer with overlapping clinical-mechanism ambitions for tinnitus.
  • Oto (formerly Oto Health): Digital/app-delivered tinnitus therapy (CBT-based) targeting the same patient population via direct-to-consumer and audiologist channels; competes for the underserved chronic-tinnitus segment Desyncra addresses.
  • Sound Relief Hearing Center: US audiology clinic network specializing in tinnitus treatment; comparable as both an authorized Desyncra provider and a competitor channel offering alternative tinnitus therapies (CBT-based and sound-based) to similar patient cohorts.

Broad incumbents

  • Cochlear Limited: Global implantable hearing-solutions company (cochlear implants, bone-conduction systems); adjacent incumbent in the same neuro-otology and ENT prescribing channel as Desyncra's therapy.
  • GN Hearing (ReSound): Hearing-aid manufacturer (parent of ReSound and Beltone) with a ReSound Relief tinnitus app and integrated tinnitus therapy features, serving the same audiologist distribution channel that Desyncra targets.
  • Sonova (Phonak): Swiss parent of Phonak and other hearing-aid brands offering tinnitus therapy features inside hearing aids; a broad incumbent whose products sit alongside CR® in audiologists' tinnitus recommendation set.
  • Widex: Major hearing-aid manufacturer offering the Widex Zen tinnitus therapy/sound therapy program integrated into its hearing aids; competes for the same audiologist-channel tinnitus patient and shares Desyncra's positioning as an evidence-led therapy.
  • Signia (WS Audiology): Global hearing-aid brand with a dedicated tinnitus therapy feature set (Notch Therapy, built-in tinnitus notch) bundled with its core hearing-aid portfolio, offering ENT/audiology clinics an incumbent alternative to a standalone neuromodulation therapy.
  • Oticon: Hearing-aid incumbent with a Tinnitus SoundSupport offering and clinical-evidence-heavy go-to-market through audiologists; competes for the same audiology-channel prescribing decision as Desyncra's CR® therapy.

Direct peers

  • Neuromod Devices: Ireland-based developer of Lenire, a bimodal (auditory + tongue) neuromodulation device FDA-cleared for tinnitus — the closest head-to-head competitor to Desyncra's CR® Neuromodulation, with a comparable clinic-distribution model.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Desyncra Technologies social profiles

Digital presence

Desyncra Technologies compliance and trust

Trust signal

Compliance2 records

Desyncra Technologies financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Desyncra Technologies leadership team

Management profile

Number of profiles

Desyncra Technologies subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Desyncra Technologies funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Desyncra Technologies M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Desyncra Technologies

What does Desyncra Technologies do?

Desyncra develops and supplies Desyncra™ for Tinnitus, a neuroscientific CR® Neuromodulation therapy that uses acoustic stimulation to disrupt hyperactivity in tinnitus neuronal networks. The therapy is delivered through customized iPod devices with custom-designed earphones over a 36-week treatment course, with therapeutic tones personalized to each patient via a proprietary pitch-matching procedure. The product carries FDA clearance and CE Mark and is distributed exclusively through authorized audiology and ENT clinics rather than sold directly to patients.

Is Desyncra Technologies a public or private company?

Desyncra Technologies is a private company. It is classified as unknown and is currently operating.

When was Desyncra Technologies founded?

Desyncra Technologies was founded in 2015. It employs 1 to 10 people.

Where is Desyncra Technologies based?

Desyncra Technologies is headquartered in London, United Kingdom, in the Europe region.

How does Desyncra Technologies make money?

Two revenue lines are on record. Medical Device Technology Licensing is the primary driver. The others are clinic Network Distribution.

Who are Desyncra Technologies's main competitors?

Emerging players on record are MicroTransponder, Oto (formerly Oto Health) and Sound Relief Hearing Center. Broad incumbents are Cochlear Limited, GN Hearing (ReSound), Sonova (Phonak), Widex, Signia (WS Audiology) and Oticon. Neuromod Devices is listed as a direct peer.

Does Desyncra Technologies have an API?

No public API is recorded for Desyncra Technologies.

What industry is Desyncra Technologies in?

Desyncra Technologies's product category is Neuromodulation Medical Devices. Its primary akta.pro industry code is HLACANAC, Non-prescription / OTC Digital Therapeutics. Its NAICS code is 334510 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales